EDIT Presents EDIT-401 Preclinical Data Showing ~90% Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates, Plans CTN Submission by Mid-2026
Editas Medicine, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $3.34
+25% in 1d after detection
Post-detection moves
1h
-12%
1d
+25%
3d
+21%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS